Follow-up Repeat broad and inflammation markers after 6-12 weeks if symptoms change or the protocol continues
A 2025 narrative review of musculoskeletal research described both the regenerative findings and the open questions about translation to human clinical use (PMID 40789979)
Conducting a long-term experiment
Nothing in this article is medical advice, and any decision to start, stop, or adjust a protocol, especially with a pre-existing metabolic or oncologic history, should involve a qualified clinician
3-aminobenzamide (3-AB) is a competitive inhibitor of PARP enzymes, particularly PARP1 171,172
F., Casabianca, A., et al